Introduction
Cisplatin is an effective treatment in a variety of cancer entities. However, in addition to toxic side effects, the occurrence of acquired resistance frequently compromises therapy outcome, and several resistance mechanisms are the focus of current research efforts. Of these mechanisms, an increased intracellular formation of biologically inactive adducts with proteins and peptides seems to be a relevant factor contributing to the acquisition of resistance [1] . It has been shown, for example, that cisplatin, after entering the cell, can react with water molecules and readily bind to nucleophilic species such as glutathione (GSH), metallothioneins, and other proteins prior to reaching the cell DNA [1, 2] .
In a previous project, we used CFDA-Pt, a fluorescent cisplatin analogue [3] , to identify other intracellular binding partners of cisplatin. Following 2D gel electrophoresis of cytosolic proteins, an ESI-MS/MS analysis of fluorescent adducts revealed several proteins binding CFDA-Pt [4] . One of these was glucose-regulated protein 78 kDa (GRP78). In several cancer cell line models of a variety of tumor types it has been shown that GRP78 up-regulation occurs intrinsically or can be induced by cisplatin treatment [5, 6] . Recently, Cali et al. [7] reported an increased GRP78 expression in endometrial tumors. Melanoma cells were sensitized to cisplatin treatment after siRNA-mediated knockdown of GRP78 [8] . Lin et al. [9] showed an upregulation of GRP78 in ER stress-tolerant lung cancer cells (A460et and A549et). In these cells, cisplatin resistance could be reversed by knockdown of GRP78.
Since GRP78 has been identified as an important binding partner for CFDA-Pt we hypothesized that it may contribute to cisplatin resistance by deactivating reactive platinum species in the cytoplasm before these can reach their target, the cell DNA. We therefore investigated the effect of siRNAmediated knockdown of GRP78 on the cytotoxicity of cisplatin in A2780 ovarian cancer cells and their cisplatin-resistant variant A2780cis.
Material and methods

Cell culture
The human ovarian carcinoma cell line A2780 and the cisplatin-resistant variant A2780cis were cultivated as monolayers in RPMI-1640™ medium with 10% fetal calf serum, 0.6 mM L-glutamine, 100 I.E./mL penicillin, and 0.1 mg/mL streptomycin at 37 °C with 5% CO 2 .
Small-interfering RNA knockdown of GRP78
A2780 and A2780cis cells were seeded in 6-well plates at 0.5 × 10 6 cells per well and incubated for 24 hours. The siRNA against GRP78 (Hs-HSPA5-6 Flexi tube, functionally verified siRNA, SI02780554) and the negative control siRNA (AllStars Negative Control siRNA, SI03650318) were obtained from Qiagen GmbH, Hilden, Germany. Cells were transfected using the K2 TM transfection system (Biontex Laboratories GmbH, Planegg, Germany) with 50 pmol/well of siRNA in antibiotic-free medium. Efficiency of knockdown was assessed using western blot analysis.
Cytotoxicity
The cytotoxicity of cisplatin after siRNA knockdown of GRP78 was determined using an MTT-based assay (MTT = 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide). Cells were allowed to attach in 96-well plates overnight prior to carrying out the knockdown. Subsequently, cells were incubated with increasing concentrations of cisplatin for 48 hours. The EC 50 (drug concentration which produces 50% of the maximum possible response) and pEC 50 (= -log EC 50 ) values were estimated using the GraphPad Prism™ analysis software package (GraphPad Software, San Diego, CA, USA) by means of non-linear regression (sigmoidal dose response). Resistance factors were calculated by the ratio of EC 50 values of A2780cis to A2780 cells.
Western blot analysis
Cells were lysed in RIPA buffer, separated by SDS/PAGE, and transferred to polyvinylidene difluoride (PVDF) membranes. Non-specific binding to the membranes was blocked using 5% skim milk in Tris-buffered saline (TBS) with 0.2% Tween for 1 hour. After washing, membranes were incubated overnight with antibodies against GRP78 at 1 : 1,000 (GTX102580, GeneTex Inc., Irvine, CA, USA) and GAPDH at 1 : 10,000 (GTX100118, GeneTex Inc.) dilutions. Secondary antibody goat anti-rabbit (4030-05, SouthernBiotech, Birmingham, AL, USA), was used at 1 : 2,000 and 1 : 20,000, respectively. Chemiluminescence was detected after incubation with Pierce TM ECL western blotting substrate (Thermo Scientific, Rockford, IL, USA) on a ChemiDoc™ XRS+ System (Bio-Rad, Hercules, CA, USA). Densitometric analysis was carried out using Image Lab TM software (Bio-Rad).
Results
We first determined the basal expression of GRP78 and the effect of cisplatin treatment on GRP78 expression in A2780 and A2780cis cells. In contrast to previous findings [5, 6] , there was no significant effect of cisplatin on GRP78 expression detectable by western blot analysis. After treatment with 5 -20 µM of cisplatin for 6 -48 hours, GRP78 expression in A2780 and A2780cis cells did not change significantly compared to the basal expression without treatment.
To investigate if GRP78 contributes to cisplatin detoxification in the cytoplasm, we performed a transient siRNA-mediated silencing of GRP78 in A2780 and A2780cis cells. The expression of GRP78 compared to untreated control cells was reduced to 59 ± 9% and 37 ± 8% in A2780 and A2780cis cells, respectively.
We next determined cisplatin cytotoxicity using the MTT assay after GRP78 knockdown. Our results showed no significant difference between non-transfected control cells and GRP78 knockdown cells (Figure 1 ). A2780cis cells exhibited a non-significant (p = 0.11) decrease in the pEC 50 value, rather suggesting an increase in resistance. This is supported by the fact that the resistance fac- tor was increased by 40% after knockdown (RF control = 4.2 vs. RF GRP78kd = 5.8).
Conclusions
We conclude that cisplatin has no significant effect on GRP78 expression in the cell line model A2780/A2780cis. The influence of GRP78 on resistance seems to be minor since the pEC 50 did not change significantly after knockdown. In further experiments, the degree of DNA platination after knockdown will be measured in order to examine the possibility that cell signaling adaptations are able to counteract the effects of GRP78 knockdown.
